Survival analysis of contralateral prophylactic mastectomy: A question of selection bias

Annals of Surgical Oncology

Volumn 21, Issue 11, 2014, Pages 3448-3456

  Kruper, Laura ^a   Kauffmann, Rondi M ^a   Smith, David D ^a   Nelson, Rebecca A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTRALATERAL PROPHYLACTIC MASTECTOMY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; DISEASE SURVEILLANCE; ETHNICITY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; OVERALL SURVIVAL; PATIENT RISK; PROPHYLACTIC SURGICAL PROCEDURE; RISK ASSESSMENT; RISK FACTOR; SELECTION BIAS; SURVIVAL RATE; ADOLESCENT; BREAST NEOPLASMS; CANCER REGISTRY; FOLLOW UP; LYMPH NODE METASTASIS; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CALIFORNIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SEER PROGRAM; SELECTION BIAS; SURVIVAL RATE; YOUNG ADULT;

EID: 84922537383     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3930-0     Document Type: Article

References (41)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Buzdar A. Breast cancer survival on the rise: report of MD Anderson experience. Reported in advance of the 2010 Breast Cancer Symposium in Washington, DC. Available at: http://www.mdanderson.org/publications/conquest/issues/2011-spring/breast-cancer-survival.html. Accessed 18 Dec 2013.
3. Lichter AS, Lippman ME, Danforth DN Jr, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol. 1992;10:976–83.
4. Gomez SL, Lichtensztajn D, Kurian AW, et al. Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. J Clin Oncol. 2010;28:e155–7.
5. Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg. 1984;71:711–4.
6. Rosen PP, Groshen S, Kinne DW, et al. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery. 1989;106:904–10.
7. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol. 2003;56:1038–45.
8. Healey E, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characeteristics and impact on prognosis. J Clin Oncol. 1993;11:1545–52.
9. Vaittinen P, Hemmenki K. Risk factors and age–incidence relationships for contralateral breast cancer. Int J Cancer. 2000;88:998–1002.
10. Peralta EA, Ellenhorn JD, Wagman LD, et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180:439–45.
11. McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal history and family history of breast cancer. J Clin Oncol. 2001;19:3938–43.
12. Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a Cancer Research Network project. J Clin Oncol. 2005;23:4275–86.
13. Van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93:287–92.
14. Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.
15. Tuttle TM, Jarosek S Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27:1362–7.
16. Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol. 2012;19:2600–6.
17. Yao K, Winchester DJ, Czechura T, Huo D. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002. Breast Cancer Res Treat. 2013;142:465–76.
18. Surveillance, Epidemiology, and End Results. Available at: http://seer.cancer.gov. Accessed 15 Sep 2013.
19. Surveillance, Epidemiology, and End Results (SEER) Program. Research data, 1973–2010. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission. Available at: http://seer.cancer.gov. Accessed 15 Sep 2013.
20. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer;2010.
21. Brewster AM, Bedrosian I, Parker PA, et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012;118:5637–43.
22. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26:734–53.
23. Parsons LS. Reducing bias in a propensity score marched-pair sample using greedy matching techniques group (paper 214-26). In: Proceedings of the 26th Annual SAS Users Group International Conference, April 2001.
24. Narod SA. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat. 2011;128:581–3.
25. Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. Br Med J. 2014;348:1–11.
26. Evans DGR, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140:135–42.
27. Tracy MS, Rosenberg SM, Dominici L, Partridge AH. Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research. Breast Cancer Res Treat. 2013;140:447–52.
28. McLaughlin CC, Lillquist PP, Edge SB. Surveillance of prophylactic mastectomy: trends in use from 1995–2005. Cancer. 2009;115:5404–12.
29. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97:439–48.
30. Newman L. Disparities in breast cancer. Curr Probl Cancer. 2007;31:134–56.
31. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163:49–56.
32. Newman L, Mason J, Cote D, et al. Afrincan-American ethnicity, socioeconomic status and breast cancer survival. Cancer. 2002;94:2844–54.
33. Bertelsen L, Bernstein L, Olsen JH, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women’s Environment, Cancer and Radiation Epidemiology study. J Natl Cancer Inst. 2008;100:32–40.
34. Broet P, Rochefordiere A, Schall SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995;13:1578–83.
35. Schaapveld M, Visser O, Louwman WJ, etal. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110:189–97.
36. Baum M, Budzar AU, Cuzick J, et al; ATAC Trialists Group. Anastrazole alone or in combination with tamoxifen versus tamoxfien alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002;359:2131–9.
37. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Ajuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.
38. Nichols HB, Gonzalez AB, Lacey JV, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29:1564–9.
39. Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17:2702–9.
40. Bedrosian I, Hu C, Chang G. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102:401–9.
41. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;(11):CD002748.